GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alder BioPharmaceuticals Inc (NAS:ALDR) » Definitions » Owner Earnings per Share (TTM)

Alder BioPharmaceuticals (Alder BioPharmaceuticals) Owner Earnings per Share (TTM) : 0.00 (As of Jun. 2019)


View and export this data going back to 2014. Start your Free Trial

What is Alder BioPharmaceuticals Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Alder BioPharmaceuticals's Owner Earnings per Share (TTM) ended in Jun. 2019 was $0.00. It's Price-to-Owner-Earnings ratio for today is 0.


The historical rank and industry rank for Alder BioPharmaceuticals's Owner Earnings per Share (TTM) or its related term are showing as below:



ALDR's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 34.175
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

Alder BioPharmaceuticals's Earnings per Share (Diluted) for the three months ended in Jun. 2019 was $-0.72. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2019 was $-4.45. It's PE Ratio ratio for today is At Loss.

Alder BioPharmaceuticals's EPS without NRI for the three months ended in Jun. 2019 was $-0.72. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2019 was $-4.45. It's PE Ratio without NRI ratio for today is At Loss.


Alder BioPharmaceuticals Owner Earnings per Share (TTM) Historical Data

The historical data trend for Alder BioPharmaceuticals's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alder BioPharmaceuticals Owner Earnings per Share (TTM) Chart

Alder BioPharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial - - - -3.71 -4.22

Alder BioPharmaceuticals Quarterly Data
Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.80 -3.93 -4.22 -3.99 -3.61

Competitive Comparison of Alder BioPharmaceuticals's Owner Earnings per Share (TTM)

For the Biotechnology subindustry, Alder BioPharmaceuticals's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alder BioPharmaceuticals's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alder BioPharmaceuticals's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Alder BioPharmaceuticals's Price-to-Owner-Earnings falls into.



Alder BioPharmaceuticals Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Alder BioPharmaceuticals's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income -317.35
Depreciation, Depletion and Amortization 2.03
Change In Deferred Tax 0.00
5Y Average of Maintenance Capital Expenditure 2.88
Change In Working Capital 16.74
Shares Outstanding (Diluted Average) 83.48

1. Start with "Net Income" from income statement. Alder BioPharmaceuticals's Net Income for the trailing twelve months (TTM) ended in Jun. 2019 was $-317.35 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Alder BioPharmaceuticals's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Jun. 2019 was $2.03 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Alder BioPharmaceuticals's Change In Deferred Tax for the trailing twelve months (TTM) ended in Jun. 2019 was $0.00 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $2.88 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Alder BioPharmaceuticals's 5-Year Average Maintenance Capital Expenditure = $2.88 Mil

5. "Change In Working Capital" is from cashflow statement. Alder BioPharmaceuticals's Change In Working Capital for the trailing twelve months (TTM) ended in Jun. 2019 was $16.74 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Alder BioPharmaceuticals's Shares Outstanding (Diluted Average) for the months ended in Jun. 2019 was 83.480 Mil.

Alder BioPharmaceuticals's Onwer Earnings Per Share for Jun. 2019 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( -317.354 +2.029+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-2.8808+16.742)/83.480
=0.00

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=18.88/0.00
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Alder BioPharmaceuticals Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of Alder BioPharmaceuticals's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Alder BioPharmaceuticals (Alder BioPharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
11804 North Creek Parkway South, Bothell, WA, USA, 98011
Alder BioPharmaceuticals is a biotechnology company that seeks to discover, develop, and commercialize therapeutic antibodies. The company's antibody platform seeks to maximize efficacy, as well as speed of onset and durability of therapeutic response. Alder's product pipeline addresses diseases where patients have limited medical options or where current medical options may not meet the needs of a substantial number of patients. The company operates in two geographic regions: the United States and Australia. The vast majority of the Alder's assets are located in the United States, where the vast majority of its revenue is also generated.
Executives
Paul Rutherford Carter director SOUTH BUILDING, 2 ROUNDWOOD AVENUE, STOCKLEY PARK X0 UB11 1AF
H Lundbeck A S 10 percent owner 9 OTTILIAVEJ DK 2500 VALBY, COPENHAGEN, DENMARK G7 00000
Clay B Siegall director 21823 30TH DR SE, BOTHELL WA 98021
Paul Streck officer: Chief Medical Officer 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Wendy L Yarno director
Carlos Campoy officer: Chief Financial Officer 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Robert Azelby director, officer: President and CEO 307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109
Heather Preston director C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, FORT WORTH TX 76102
Jeremy Green director 45 W. 27TH STREET, FLOOR 11, NEW YORK NY 10001
Redmile Group, Llc director ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Paul B Cleveland director C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304
Alan Bruce Montgomery director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Mark James Litton officer: Chief Business Officer 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Deepika Pakianathan director 160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402
Eric G Carter officer: Interim Chief Medical Officer C/O KING PHARMACEUTICALS, INC., 501 FIFTH STREET, BRISTOL TN 37620

Alder BioPharmaceuticals (Alder BioPharmaceuticals) Headlines

From GuruFocus